CN112771040A - 单环内酰胺化合物及其应用 - Google Patents

单环内酰胺化合物及其应用 Download PDF

Info

Publication number
CN112771040A
CN112771040A CN201980062340.8A CN201980062340A CN112771040A CN 112771040 A CN112771040 A CN 112771040A CN 201980062340 A CN201980062340 A CN 201980062340A CN 112771040 A CN112771040 A CN 112771040A
Authority
CN
China
Prior art keywords
amino
alkyl
alkoxy
hydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980062340.8A
Other languages
English (en)
Other versions
CN112771040B (zh
Inventor
王勇
赵立文
王亚洲
全旭
王小伟
张晓平
吕坤志
林泽琦
张健
许涛
常玉杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Sanhome Pharmaceutical Co Ltd
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Publication of CN112771040A publication Critical patent/CN112771040A/zh
Application granted granted Critical
Publication of CN112771040B publication Critical patent/CN112771040B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

涉及一类单环内酰胺化合物及其应用，具体地，提供了式(I)所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗细菌感染的用途。该化合物具有优异抑菌活性，非常有希望成为细菌感染的治疗剂。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980062340.8A 2018-11-13 2019-11-12 单环内酰胺化合物及其应用 Active CN112771040B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018113489086 2018-11-13
CN201811348908 2018-11-13
PCT/CN2019/117472 WO2020098635A1 (zh) 2018-11-13 2019-11-12 单环内酰胺化合物及其应用

Publications (2)

Publication Number Publication Date
CN112771040A true CN112771040A (zh) 2021-05-07
CN112771040B CN112771040B (zh) 2022-10-18

Family

ID=70617707

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980062340.8A Active CN112771040B (zh) 2018-11-13 2019-11-12 单环内酰胺化合物及其应用
CN201911103555.8A Active CN111171014B (zh) 2018-11-13 2019-11-13 单环内酰胺化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911103555.8A Active CN111171014B (zh) 2018-11-13 2019-11-13 单环内酰胺化合物及其应用

Country Status (8)

Country Link
US (1) US20220002288A1 (zh)
EP (1) EP3882246A4 (zh)
JP (1) JP2022507470A (zh)
KR (1) KR20210083285A (zh)
CN (2) CN112771040B (zh)
CA (1) CA3119394A1 (zh)
TW (1) TW202024068A (zh)
WO (1) WO2020098635A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物及其制备方法和应用
CN115246799A (zh) * 2021-12-15 2022-10-28 温州医科大学 化合物及其制备方法和包含该化合物的纳米光热试剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368040A (zh) * 2015-12-15 2018-08-03 默沙东公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
CN108778273A (zh) * 2016-03-07 2018-11-09 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557082A4 (en) * 2010-04-05 2013-08-28 Shionogi & Co CEPHEM COMPOUND COMPRISING A CATÉCHOL GROUP
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
AU2015236369B2 (en) 2014-03-24 2017-02-16 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
BR112019012994A2 (pt) * 2016-12-21 2019-12-03 Aicuris Gmbh & Co Kg terapia de combinação com compostos de b-lactama de amidina substituída e inibidores de b-lactamase para infecções com cepas bacterianas resistentes a antibiótico
US11459323B2 (en) * 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368040A (zh) * 2015-12-15 2018-08-03 默沙东公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
CN108778273A (zh) * 2016-03-07 2018-11-09 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法

Also Published As

Publication number Publication date
CN112771040B (zh) 2022-10-18
WO2020098635A1 (zh) 2020-05-22
CN111171014A (zh) 2020-05-19
CA3119394A1 (en) 2020-05-22
US20220002288A1 (en) 2022-01-06
TW202024068A (zh) 2020-07-01
KR20210083285A (ko) 2021-07-06
EP3882246A1 (en) 2021-09-22
JP2022507470A (ja) 2022-01-18
EP3882246A4 (en) 2021-12-29
CN111171014B (zh) 2023-11-07

Similar Documents

Publication Publication Date Title
CN109715630B (zh) β-内酰胺酶抑制剂化合物
JP2016509594A (ja) ボロン酸誘導体及びその治療的使用
CN112771040B (zh) 单环内酰胺化合物及其应用
CN110520413B (zh) 大环广谱抗生素
CN112074507B (zh) 作为抗菌素的化合物
US12110263B2 (en) Ketone inhibitors of lysine gingipain
CN108463461A (zh) 头孢烯化合物、其制备和用途
US20180093985A1 (en) Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections
WO2021115444A1 (zh) 单环β-内酰胺化合物及其用途
US11738010B2 (en) Oxazolidinones as TarO inhibitors
CN114085162B (zh) 金属β-内酰胺酶抑制剂或其药学上可接受的盐及其制备方法和应用
CA2615886A1 (en) Bicyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic
KR20050037583A (ko) 베타-락타마제 억제제 전구약물
CN111196808B (zh) 二氮杂双环类化合物及其应用
JP2012006899A (ja) 新規チオフェンカルボキサミド誘導体及びその医薬用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046660

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant